Related Experiment Video
Updated: Apr 1, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies]
J D Rebibo1, C Pfister2, A Giwerc1
1Service d'urologie et transplantation, centre hospitalier et universitaire de Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
Objective:
To assess the prognostic value of clinical and biological features in patients treated with second-line targeted therapies (TT) for a metastatic renal cell carcinoma (mRCC).
Material And Methods:
A retrospective study was performed including 60 patients treated with second-line TT from 2006 to 2013. Clinical and biological features were collected, including TT-induced toxicities, Heng and MSKCC prognostic scores, and renal function. Overall survival (OS) and progression-free survival (PFS) were assessed using univariate and multivariate analysis.
Results:
The median age was 61 years [39-81]. MSKCC and Heng scores were significantly prognostic for OS and PFS (P<0.05). Hypo-albuminemia, anemia and brain metastasis were associated with poorer OS and PFS (P<0.05). Severe induced toxicities had a prognostic impact with higher OS (26 months vs 10 months, P=0.003) and PFS (5 months vs 4 months, P=0.047). Renal function impairment at the initiation of the second line was also associated with higher survival (OS=24 months vs 9 months, P=0.035 and PFS=7 months vs 4 months, P=0.043). On multivariate analysis, induced toxicity was found as an independent factor of good prognosis for OS (HR=0.36; P=0.01).
Conclusion:
Our results suggested that renal function impairment and TT-induced toxicities in the second line of treatment for mRCC have a potential prognostic interest as it had previously been reported for the first line of TT.
Level Of Evidence:
5.
Insights
In metastatic renal cell carcinoma (mRCC) patients receiving second-line targeted therapies (TT), impaired renal function and TT-induced toxicities predict better survival. These factors offer prognostic value in mRCC treatment.
Area of Science:
- Oncology
- Clinical Pharmacology
- Biostatistics
Background:
- Metastatic renal cell carcinoma (mRCC) poses significant treatment challenges.
- Second-line targeted therapies (TT) are crucial for managing advanced mRCC.
- Identifying prognostic factors is essential for optimizing patient outcomes.
Purpose of the Study:
- To evaluate the prognostic significance of clinical and biological features in mRCC patients undergoing second-line TT.
- To determine factors associated with overall survival (OS) and progression-free survival (PFS).
Main Methods:
- Retrospective analysis of 60 mRCC patients treated with second-line TT (2006-2013).
- Collected data included TT-induced toxicities, prognostic scores (Heng, MSKCC), and renal function.
- OS and PFS assessed via univariate and multivariate analyses.
Main Results:
- MSKCC and Heng scores were significant prognostic indicators for OS and PFS.
- Hypoalbuminemia, anemia, and brain metastases correlated with poorer survival.
- Severe TT-induced toxicities and renal function impairment at treatment initiation were associated with improved OS and PFS.
- Multivariate analysis identified induced toxicity as an independent factor for good prognosis (OS).
Conclusions:
- Renal function impairment and TT-induced toxicities in second-line mRCC treatment possess prognostic value.
- These findings align with previous observations from first-line TT studies.
- These factors may aid in predicting outcomes for mRCC patients receiving targeted therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...